Urea Cycle Disorder Manufacturers, Suppliers & Companies
-
Manufacturerbased in Oxford, UNITED KINGDOM
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on improving the natural delivery capabilities of exosomes, and developing an entirely new class of therapeutics. Backed by leading venture capital groups and ...
Evox - Model Type I - Citrullinemia
The second urea cycle disorder indication to be targeted by Evox is Citrullinemia type I, which is caused by a mutation in the ASS1 gene leading to a deficiency in hepatic enzyme arginosuccinate ...
CONTACT SUPPLIER -
Technologybased in Gaithersburg, MASSACHUSETTS (USA)
In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly ...
Model SEL-313 - Gene Therapy Program for the Treatment of Ornithine Transcarbamylase (OTC)
Selecta’s wholly owned gene therapy program for the treatment of ornithine transcarbamylase (OTC) deficiency is expected to enter the clinic in 2022. OTC deficiency is a genetic disorder urea ...
CONTACT SUPPLIER
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you